Dr. Moskowitz on the ALCANZA Trial in CTCL
5 Visningar
• 08/09/23
0
0
Bädda in
administrator
Prenumeranter
Alison J. Moskowitz, MD, clinical director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, discusses the data that led to the approval of brentuximab vedotin (Adcetris) in patients with cutaneous T-cell lymphoma (CTCL).
Visa mer
Facebook-kommentarer
SORT BY-
Toppkommentarer
-
Senaste kommentarerna